ZBHZimmer Biomet

$94.22

The financials

Zimmer Biomet by the numbers

Zimmer Biomet (ZBH) reported revenue of $2.09B in Q1 2026 (quarter ended Mar 31, 2026), up 9.3% from the same quarter a year earlier. That came with a gross margin of 72% and net income of $238M (11% of revenue). For the full year FY2025, revenue was $8.23B (+7.2% year on year) and net income $705M. Its largest product in Jun 2026 was Knees at $829M, 38% of the disclosed total, ahead of SET at 27%.

Zimmer Biomet income statement, Q1 2026 against the same quarter a year earlier
Income statementQ1 2026Q1 2025Change
Revenue$2.09B$1.91B+9.3%
Gross profit$1.51B$1.36B+11%
Operating income$373M$292M+28%
Net income$238M$182M+31%
Diluted EPS$1.22$0.91+34%
Revenue by product, Jun 2026, as reported to the SEC
ProductRevenueShare
Knees$829M38%
SET$586M27%
Hips$563M26%
Technology And Data Bone Cement And Surgical$199M9.2%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Jun 2026Total $2.18B (+4.3%)
Technology And Data Bone Cement And Surgical grew +21% year on yearKnees +0.35% year on year
  • Knees$828.9MQoQ +0.04%year on year +0.35%
  • SET$586.0MQoQ +4.2%year on year +6.4%
  • Hips$562.7MQoQ +7.4%year on year +5.0%
  • Technology And Data Bone Cement And Surgical$199.4MQoQ +16%year on year +21%
Segment sum = 100% of reported consolidated revenue · Latest source: 10-Q filed 2026-08-05, SEC EDGAR